Orgenesis EBITDA Margin 2013-2021 | ORGS

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Orgenesis (ORGS) over the last 10 years. The current EBITDA margin for Orgenesis as of September 30, 2021 is .
Orgenesis EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2021-09-30 $0.03B $-0.06B -193.55%
2021-06-30 $0.02B $-0.06B -258.33%
2021-03-31 $0.02B $-0.09B -580.00%
2020-12-31 $0.01B $-0.09B -1175.00%
2020-09-30 $0.01B $-0.05B -657.14%
2020-06-30 $0.01B $-0.04B -666.67%
2020-03-31 $0.01B $-0.02B -340.00%
2019-12-31 $0.00B $-0.02B -600.00%
2019-09-30 $0.01B $-0.02B -230.00%
2019-03-31 $0.01B $-0.02B -114.29%
2018-12-31 $0.02B $-0.01B -61.11%
2018-05-31 $0.01B $-0.01B -80.00%
2018-02-28 $0.01B $-0.01B -100.00%
2017-08-31 $0.01B $-0.01B -142.86%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.083B $0.008B
Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09